Patents by Inventor Kenneth G. Draper

Kenneth G. Draper has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method and reagent for treatment of diseases caused by expression of the c-myc gene
    Publication number: 20040033568
    Abstract: The present invention relates to an enzymatic RNA molecule which cleaves mRNA derived from c-myc gene.
    Type: Application
    Filed: December 18, 2002
    Publication date: February 19, 2004
    Applicant: Ribozyme Pharmaceuticals, Inc.
    Inventors: James D. Thompson, Kenneth G. Draper
  • Method and reagent for treatment of diseases caused by expression of the c-myc gene
    Publication number: 20030162264
    Abstract: The present invention relates to an enzymatic RNA molecule which cleaves mRNA derived from c-myc gene.
    Type: Application
    Filed: December 23, 2002
    Publication date: August 28, 2003
    Applicant: Ribozyme Pharmaceuticals, Inc.
    Inventors: James D. Thompson, Kenneth G. Draper
  • Method and reagent for treatment of diseases by expression of the c-Myc gene
    Patent number: 6544755
    Abstract: An enzymatic RNA molecule which cleaves mRNA associated with development or maintenance of Burkitt's lymphoma or acute lymphocytic leukemia.
    Type: Grant
    Filed: February 7, 1994
    Date of Patent: April 8, 2003
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventors: James D. Thompson, Kenneth G. Draper
  • Ribozyme treatment of diseases or conditions related to levels of NF-kappaB
    Publication number: 20030003469
    Abstract: Enzymatic RNA molecules which cleave rel A mRNA.
    Type: Application
    Filed: January 23, 2002
    Publication date: January 2, 2003
    Applicant: Ribozyme Pharmaceuticals, Inc.
    Inventors: Dan T. Stinchcomb, Kenneth G. Draper, James McSwiggen
  • Method and reagent for treatment of lung cancer and other malignancies caused by the deregulation of L-MYC gene expression
    Patent number: 6492512
    Abstract: An enzymatic RNA molecule which cleaves mRNA associated with development or maintenance of lung cancer.
    Type: Grant
    Filed: August 26, 1992
    Date of Patent: December 10, 2002
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventors: James D. Thompson, Kenneth G. Draper
  • Enzymatic nucleic acid treatment of diseases or conditions related to levels of NF-kappa B
    Publication number: 20020177568
    Abstract: The present invention relates to nucleic acid molecules, including antisense and enzymatic nucleic acid molecules, such as hammerhead ribozymes, DNAzymes, allozymes and antisense, which modulate the expression or function of NFKB genes, such as REL-A, REL-B, REL (c-rel), NFKB1 (p105/p50) and NFKB2 (p100)/p52/p49).
    Type: Application
    Filed: May 23, 2001
    Publication date: November 28, 2002
    Inventors: Dan T. Stinchcomb, James McSwiggen, Kenneth G. Draper
  • Method and reagent for inhibiting herpes simplex virus replication
    Patent number: 6440719
    Abstract: An enzymatic RNA molecule which specifically cleaves a herpes simplex virus mRNA molecule.
    Type: Grant
    Filed: August 8, 2000
    Date of Patent: August 27, 2002
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventor: Kenneth G. Draper
  • Ribozyme treatment of diseases or conditions related to levels of intercellular adhesion molecule-1 (CAM-1)
    Patent number: 6436644
    Abstract: The present invention relates to enzymatic RNA molecules which cleave ICAM-1 mRNA.
    Type: Grant
    Filed: June 7, 2000
    Date of Patent: August 20, 2002
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventors: Susan Grimm, Dan T. Stinchcomb, James McSwiggen, Sean Sullivan, Kenneth G. Draper
  • Method and reagent for inhibiting herpes simplex virus replication
    Patent number: 6432704
    Abstract: An enzymatic RNA molecule which specifically cleaves a herpes simplex virus mRNA molecule.
    Type: Grant
    Filed: June 28, 1999
    Date of Patent: August 13, 2002
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventor: Kenneth G. Draper
  • Ribozyme treatment of diseases or conditions related to levels of NF-&kgr;B
    Patent number: 6410224
    Abstract: Enzymatic RNA molecules which cleave rel A mRNA.
    Type: Grant
    Filed: December 23, 1996
    Date of Patent: June 25, 2002
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventors: Dan T. Stinchcomb, Kenneth G. Draper, James McSwiggen
  • Oligonucleotide therapies for modulating the effects of herpesviruses
    Patent number: 6310044
    Abstract: Compositions and methods are provided for the treatment and diagnosis of herpesvirus infections. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with RNA or DNA deriving from a gene corresponding to one of the open reading frames UL5, UL8, UL9, UL13, UL29, UL30, UL39, UL40, UL42 AND UL52 of herpes simplex virus type 1. The oligonucleotide comprises nucleotide units sufficient in identity and number to effect said specific hybridization. In other preferred embodiments, the oligonucleotides are specifically hybridizable with a translation initiation site; it is also preferred that they comprise the sequence CAT. Methods of treating animals suspected of being infected with herpesvirus comprising contacting the animal with an oligonucleotide specifically hybridizable with RNA or DNA deriving from one of the foregoing genes of the herpesvirus are disclosed.
    Type: Grant
    Filed: April 28, 1992
    Date of Patent: October 30, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Kenneth G. Draper, David J. Ecker, Christopher K. Mirabelli, Stanley T. Crooke
  • Method and reagent for inhibiting influenza virus replication
    Patent number: 6258585
    Abstract: An enzymatic RNA molecule which specifically cleaves an influenza virus RNA.
    Type: Grant
    Filed: February 7, 1994
    Date of Patent: July 10, 2001
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventor: Kenneth G. Draper
  • Method and reagent for inhibiting human immunodeficiency virus replication
    Patent number: 6159692
    Abstract: An enzymatic nucleic acid molecule which cleaves an immunodeficiency virus RNA in a gene required for viral replication, e.g., the nef or tat gene regions.
    Type: Grant
    Filed: February 12, 1999
    Date of Patent: December 12, 2000
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventors: Kenneth G. Draper, Bharat Chowrira, James McSwiggen, Dan T. Stinchcomb, James D. Thompson
  • Composition and method for treatment of CMV infections
    Patent number: 6153595
    Abstract: This invention concerns compositions and methods for the treatment of CMV infections. Antisense oligonucleotides are provided which are effective antiviral agents. In preferred embodiments, the oligonucleotides contain at least one 2'-methoxyethoxy modification and may be chimeric oligonucleotides.
    Type: Grant
    Filed: April 9, 1997
    Date of Patent: November 28, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Kenneth G. Draper, Daniel L. Kisner, Kevin P. Anderson, Sharon Chapman
  • Method and reagent for inhibiting hepatitis C virus replication
    Patent number: 6132966
    Abstract: An enzymatic RNA molecule which specifically cleaves RNA of a hepatitis C virus.
    Type: Grant
    Filed: April 21, 1998
    Date of Patent: October 17, 2000
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventor: Kenneth G. Draper
  • Ribozyme treatment of diseases or conditions related to levels of intercellular adhesion molecule-1 (ICAM-1)
    Patent number: 6132967
    Abstract: Enzymatic RNA molecules which cleave ICAM-1 mRNA.
    Type: Grant
    Filed: May 1, 1998
    Date of Patent: October 17, 2000
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventors: Susan Grimm, Dan T. Stinchcomb, James McSwiggen, Sean Sullivan, Kenneth G. Draper
  • Method and reagent for inhibiting hepatitis B virus replication
    Patent number: 6017756
    Abstract: An enzymatic RNA molecule which specifically cleaves RNA of a hepatitis B virus.
    Type: Grant
    Filed: February 7, 1994
    Date of Patent: January 25, 2000
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventor: Kenneth G. Draper
  • HIV nef targeted ribozymes
    Patent number: 5972704
    Abstract: An enzymatic nucleic acid molecule which cleaves an immunodeficiency virus RNA in a gene required for viral replication, e.g., the nef or tat gene regions.
    Type: Grant
    Filed: August 13, 1997
    Date of Patent: October 26, 1999
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventors: Kenneth G. Draper, Bharat Chowrira, James McSwiggen, Dan T. Stinchcomb, James D. Thompson
  • Method and reagent for inhibiting herpes simplex virus replication
    Patent number: 5972699
    Abstract: An enzymatic RNA molecule which specifically cleaves a herpes simplex virus mRNA molecule.
    Type: Grant
    Filed: April 8, 1997
    Date of Patent: October 26, 1999
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventor: Kenneth G. Draper
  • Method and reagent for inhibiting hepatitis C virus replication
    Patent number: 5869253
    Abstract: An enzymatic RNA molecule which specifically cleaves RNA of a hepatitis C virus.
    Type: Grant
    Filed: December 26, 1996
    Date of Patent: February 9, 1999
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventor: Kenneth G. Draper